- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2022 · career development · Young Investigator Award
Phase 1 study of adding navitoclax to the combination of venetoclax and decitabine for advanced myeloid malignancies
Evan Chen · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2022 · fellowship · AACR-Mirati Cancer Chemical Biology Research Fellowship
Discovery of gene regulation by non-canonical metabolite cap structures
Fatima Alghoul · Dana-Farber Cancer Institute · funded by American Association for Cancer Research
2022 · career development · Young Investigator Award
Mechanisms of Graft-Versus-Leukemia following Donor Lymphocyte Infusions in Patients with Relapsed AML after Stem Cell Transplantation
Alexandria Maurer · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2022 · career development · Career Development Award
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention Development
Andrew Hantel · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2022 · career development · Young Investigator Award
Racial, ethnic, and socioeconomic disparities in Children’s Oncology Group (COG) clinical trial participation for children with high-risk neuroblastoma
Puja Umaretiya · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2022 · career development · Young Investigator Award
Targeting Nitric Oxide Synthase (NOS) Pathway in Obesity-associated Triple-Negative Breast Cancer (TNBC)
Kai Sun · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2022 · career development · Young Investigator Award
Genomic Characterization of Locally Recurrent Prostate Cancer after Radiation Therapy
David Yang · Dana-Farber Cancer Institute · funded by Conquer Cancer Foundation
2022–2027 · cooperative agreement · U01
Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity
Andrew James Aguirre · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
A Novel Intervention for Avoidance-Related Opioid Misuse in Patients with Cancer
Miryam Yusufov · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Elucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancer
William A Freed-Pastor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R37
Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer
Matthew Gilbert Oser · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
Toni Choueiri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · career development · K00
Investigating Immune Responses to Neoantigen Cancer Vaccines using In Vivo Functionalized Lineage
Camila Robles-Oteiza · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
Matthew S Davids · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Genomic and Genomic Variation in Prostate Cancer
Timothy Richard Rebbeck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
Kent W Mouw · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Selective disruption of histone deacetylase complexes using protein interaction modulators
Marc Vidal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2029 · research · R35
Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P50
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Defining the landscape and mechanisms of protein redox regulation during aging
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2028 · career development · K00
Elucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers.
Kimberly Parker · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R00
SESORRS endoscopy for the staging and evaluation of colorectal cancer
Fay Nicolson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Andrew Hantel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Synthetic lethalities to cell cycle disruption in glioma
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2025 · career development · K01
The Role of Mitochondrial TNAP in Adaptive Thermogenesis
Yizhi Sun · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · program · P01
Mechanisms and Therapy of Chronic Graft-vs.-Host Disease
Corey S Cutler · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U24
Generating a full-length reference transcriptome for human protein-coding genes
David E. Hill · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Cyclin C-CDK8/19 kinases in development and in cancer
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U01
Altered metabolism and machine learning for pancreatic cancer early detection
Michael H. Rosenthal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2028 · career development · K00
SIRT1 Regulates RNA Stability to Promote Breast Cancer
Fangyu Wang · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R50
Molecular origins and evolution to treatment resistance in genitourinary cancers
Jihye Park · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
Cell lineage as an indicator of immune response in neuroblastoma
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2026 · research · R01
Systematic identification of minor histocompatibility antigens to address GVHD
Vincent Trien-Vinh Ho · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · research · R01
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2022–2027 · career development · K08
Novel targeted therapies for chronic myelomonocytic leukemia
Roger Vincent Belizaire · Dana-Farber Cancer Institute · funded by National Institutes of Health
